Delcath Systems (DCTH) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

DCTH Delcath Systems

Watchlist

12.640
+0.760+6.40%

Close Dec 2 16:00 ET

12.200
-0.440-3.48%

Post 19:57 ET

404.15MMarket Cap-10803P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Delcath Systems Announces FDA Clearance Of IND Application For Phase 2 Clinical Trial Of HEPZATO In Combination With Standard Of Care In Liver-Dominant Metastatic Colorectal Cancer
BenzingaDec 2 08:36 ET
Express News | Delcath Systems Inc - Primary Endpoint Data Expected by End of 2027
ReutersDec 2 08:31 ET
Express News | Delcath Systems Announces FDA Clearance of Ind Application for Phase 2 Clinical Trial of Hepzato™ in Liver-Dominant Metastatic Colorectal Cancer
ReutersDec 2 08:30 ET
Delcath Systems (NASDAQ:DCTH) Jumps 13% This Week, Taking One-year Gains to 330%
Yahoo FinanceDec 2 05:32 ET
H.C. Wainwright Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $22
Moomoo NewsNov 11 06:31 ET · Ratings
Delcath Systems: Strong Financial Performance and Strategic Growth Drive Buy Rating
TipRanksNov 11 06:17 ET · Ratings

Comments

bro why so serious

Nov 14 06:20

$Delcath Systems (DCTH.US)$ why always fall

Jaguar8

Aug 27 07:31

NEWS

$Delcath Systems (DCTH.US)$
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
Delcath Systems, Inc. (Nasdaq: DCTH) announced positive outcomes from an independent study on hepatic perfusion for uveal melanoma patients. The study, conducted by researchers at Moffitt Cancer Center, compared Delcath's HEPZATO KIT™ to immunotherapy and other liver-directed therapies. Key findings include:
1. Overall Survival (OS): Median OS ...

Trytosaveabit

Aug 26 15:03

Update

$Delcath Systems (DCTH.US)$ Reuters· 1 min ago1min
Delcath Systems, Inc. Announces Promising Results From Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors

Jaguar8

Aug 26 15:01

NEWS

$Delcath Systems (DCTH.US)$
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
Delcath Systems (Nasdaq: DCTH) announced promising results from an independent study on its CHEMOSAT® Hepatic Delivery System for liver tumors. The study, conducted at the University Hospital of Leipzig, Germany, evaluated 33 patients with various cancers, including uveal melanoma and cholangiocarcinoma. Key findings include:
- A 91% diseas...